BBPvsSBIOETF Comparison
VS
Virtus LifeSci Biotech Products ETF (BBP) and ALPS Medical Breakthroughs ETF (SBIO) belong to the same industry segment: Tomorrow's Treatments. BBP's top 1 sector exposures are Healthcare. In contrast, SBIO's top sector exposures are Healthcare and Non-Corporate. BBP is less expensive with a Total Expense Ratio (TER) of 0.34%, versus 0.5% for SBIO. BBP is up 28.1% year-to-date (YTD) with +$66M in YTD flows. SBIO performs worse with 4.3% YTD performance, and +$62M in YTD flows. Run a side-by-side ETF comparison of BBP and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
BBP vs SBIO performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/23/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | BBP SBIO | -2.17%-11.00% | +5.26%-17.10% | +28.10%+4.30% | +41.42%+26.73% | +121.19%+130.96% | +99.68%+19.37% |
| Flows | BBP SBIO | +$5M-$10M | +$26M+$21M | +$66M+$62M | +$78M+$79M | +$83M+$45M | +$76M+$6M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | BBP SBIO | +28.19%+31.85% | +26.47%+32.35% | +25.00%+31.52% | +26.86%+34.22% |
| Max drawdown | BBP SBIO | -8.70%-29.19% | -9.59%-29.19% | -25.54%-42.12% | -37.61%-52.50% |
| Max drawdown duration | BBP SBIO | 65d65d | 48d65d | 292d331d | 586d1479d |
Trading data
BBP | SBIO | |
Last sale 10/26/2026 at 1:30 PM | $102.33 | $53.78 |
| Previous close 10/23/2026 | $102.07 | $53.38 |
| Consolidated volume 10/23/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
BBP | SBIO | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/26/2026 at 1:30 PM
Live
Closed
BBP | SBIO | |
|---|---|---|
| Last price | $102.33 | $53.78 |
| 1D performance | +0.26% | +0.74% |
| AuM | $127.72 M | $183.99 M |
| E/R | 0.34% | 0.5% |
Characteristics
BBP | SBIO | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | VIRTUS Investment Partners | ALPS |
| Benchmark | LifeSci Biotechnology Products Index | S-Network Medical Breakthroughs Index |
| N° of holdings | 66 | 104 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 16, 2014 | December 30, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
BBP
USA
85.98%
Other
14.02%
SBIO
USA
89.31%
Other
10.69%
Sectors
BBP
Healthcare
98.44%
Other
1.56%
SBIO
Healthcare
100.01%
Other
-0.01%
Advertisement
Diversification
BBP
Total weight of top 15 holdings out of 15
31.08%
SBIO
Total weight of top 15 holdings out of 15
41.55%
Top 15 holdings
Data as of August 31, 2026
BBP
Moderna, Inc.
3.58%
Crinetics Pharmaceuticals, Inc.
2.94%
Omeros Corp.
2.49%
Iovance Biotherapeutics, Inc.
2.36%
Verastem, Inc.
2.15%
Precigen, Inc.
1.99%
Halozyme Therapeutics, Inc.
1.84%
Zai Lab Ltd.
1.82%
Kiniksa Pharmaceuticals International Plc
1.81%
Kura Oncology, Inc.
1.72%
BeOne Medicines Ltd.
1.70%
Rigel Pharmaceuticals, Inc.
1.69%
Nuvation Bio, Inc.
1.69%
ACADIA Pharmaceuticals, Inc.
1.67%
Protagonist Therapeutics, Inc.
1.65%
SBIO
Crinetics Pharmaceuticals, Inc.
4.60%
Apogee Therapeutics, Inc.
4.29%
CG Oncology, Inc.
3.41%
Travere Therapeutics, Inc.
3.16%
Xenon Pharmaceuticals, Inc.
2.99%
Dianthus Therapeutics, Inc.
2.96%
Oruka Therapeutics, Inc.
2.87%
ACADIA Pharmaceuticals, Inc.
2.54%
Edgewise Therapeutics, Inc.
2.31%
Definium Therapeutics, Inc.
2.23%
Dyne Therapeutics, Inc.
2.16%
Veradermics, Inc.
2.11%
Relay Therapeutics, Inc.
2.05%
Denali Therapeutics, Inc.
1.94%
Amylyx Pharmaceuticals, Inc.
1.93%
Frequently asked questions about BBP and SBIO
How have the BBP and SBIO ETFs performed in 2026?
As of October 23, 2026, BBP is up 28.1% year-to-date (YTD), while SBIO has returned 4.3%. That puts BBP better performer ahead so far this year.
Which ETF is attracting more investor money: BBP or SBIO?
Year-to-date, the BBP ETF saw +$66M in flows, compared to +$62M for SBIO.
Which ETF is more volatile: BBP or SBIO?
Over the past year, BBP had a volatility of 26.47%, while SBIO experienced 32.35%.
Which ETF is bigger: BBP or SBIO?
As of October 23, 2026, BBP holds $127.72 M in assets under management (AUM), while SBIO manages $183.99 M.
What sectors do the BBP and SBIO ETFs invest in?
BBP leans toward sectors like Healthcare. Meanwhile, SBIO focuses on Healthcare.
What are the top holdings of the BBP ETF and SBIO ETF?
BBP top holdings include Moderna, Inc., Crinetics Pharmaceuticals, Inc. and Omeros Corp.. SBIO holds in its top three: Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG Oncology, Inc..
Which ETF is more diversified: BBP or SBIO?
BBP holds 66 securities with 31.08% of its assets in the top 15. SBIO has 104 securities and a top 15 weight of 41.55%.
Advertisement
Latest news about BBP & SBIO
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Advertisement
Advertisement
